Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Chimeric Antigen Receptor-T Cells: A Pharmaceutical Scope
Alejandrina Hernández-López, Mario A. Téllez-González, Paul Mondragón‐Terán, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy
Weijie Cao, Haizhou Xing, Yingmei Li, et al.
Biomarker Research (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 104
Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia
Simona Caruso, Biagio De Angelis, Francesca Del Bufalo, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 60
Role of T cells in cancer immunotherapy: Opportunities and challenges
Hossain Ahmed, Aar Rafi Mahmud, Mohd. Faijanur - Rob Siddiquee, et al.
Cancer Pathogenesis and Therapy (2022) Vol. 1, Iss. 2, pp. 116-126
Open Access | Times Cited: 54
ST3GAL1 and βII-spectrin pathways control CAR T cell migration to target tumors
Yeonsun Hong, Brandon L. Walling, Hye-Ran Kim, et al.
Nature Immunology (2023) Vol. 24, Iss. 6, pp. 1007-1019
Open Access | Times Cited: 28
Potential role of immunotherapy and targeted therapy in the treatment of cancer: A contemporary nursing practice
Hamad Ghaleb Dailah, Abdullah Abdu Hommdi, Mahdi Dafer Koriri, et al.
Heliyon (2024) Vol. 10, Iss. 2, pp. e24559-e24559
Open Access | Times Cited: 10
Tri-specific tribodies targeting 5T4, CD3, and immune checkpoint drive stronger functional T-cell responses than combinations of antibody therapeutics
Margherita Passariello, Lorenzo Manna, Rosa Rapuano Lembo, et al.
Cell Death Discovery (2025) Vol. 11, Iss. 1
Open Access | Times Cited: 1
Advancing Immunotherapies for HPV-Related Cancers: Exploring Novel Vaccine Strategies and the Influence of Tumor Microenvironment
Anna Jéssica Duarte Silva, Ingrid Andrêssa de Moura, Marco Antonio Turiah Machado da Gama, et al.
Vaccines (2023) Vol. 11, Iss. 8, pp. 1354-1354
Open Access | Times Cited: 11
Promising Cellular Immunotherapy for Colorectal Cancer Using Classical Dendritic Cells and Natural Killer T Cells
Mahmoud Singer, Jennifer Valerin, Zhuoli Zhang, et al.
Cells (2025) Vol. 14, Iss. 3, pp. 166-166
Open Access
Expanding the Horizons of CAR-T Cell Therapy: A Review of Therapeutic Targets Across Diverse Diseases
Alejandrina Hernández-López, Alberto Olaya‐Vargas, Juan Carlos Bustamante‐Ogando, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 2, pp. 156-156
Open Access
Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T‐cellular therapy development
Johannes Kast, Saeideh Nozohouri, Di Zhou, et al.
Clinical and Translational Science (2022) Vol. 15, Iss. 9, pp. 2057-2074
Open Access | Times Cited: 18
Childhood leukemias in Mexico: towards implementing CAR-T cell therapy programs
Juan Carlos Bustamante‐Ogando, Alejandrina Hernández-López, César Alejandro Galván-Díaz, et al.
Frontiers in Oncology (2024) Vol. 13
Open Access | Times Cited: 3
CAR-T Cell Therapy: Managing Side Effects and Overcoming Challenges
Maryam Golmohammadi, Negar Noorbakhsh, Maria Kavianpour
Advanced Biomedical Research (2025) Vol. 14, Iss. 1
Open Access
BCMA-targeted therapies in multiple myeloma: advances, challenges and future prospects
Ruhul Amin, Biplab Kumar Dey, Ronald Darwin, et al.
Medical Oncology (2025) Vol. 42, Iss. 6
Closed Access
A simple and effective method to purify and activate T cells for successful generation of chimeric antigen receptor T (CAR-T) cells from patients with high monocyte count
Haiying Wang, Shih-Ting Tsao, Mingyuan Gu, et al.
Journal of Translational Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 15
Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma
Jiaying Wu, Yang Cao, Qi Zhang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 11
Cytotoxicity - Understanding Cellular Damage and Response

IntechOpen eBooks (2022)
Closed Access | Times Cited: 9
DMPK perspective on quantitative model analysis for chimeric antigen receptor cell therapy: Advances and challenges
Akihiko Goto, Yuu Moriya, Miyu Nakayama, et al.
Drug Metabolism and Pharmacokinetics (2024) Vol. 56, pp. 101003-101003
Open Access | Times Cited: 1
Chimeric Antigen Receptor-T (CAR-T) Cells as “Living Drugs”: A Clinical Pharmacist Perspective
Ciara Murnane, N. Gardiner, Olga Crehan, et al.
Journal of Clinical Pharmacy and Therapeutics (2024) Vol. 2024, pp. 1-18
Open Access | Times Cited: 1
Adverse events associated with chimeric antigen receptor T-cell therapy in ophthalmology: a narrative review
Sara Sarwar, Unood Riaz, Abraish Ali, et al.
Annals of Medicine and Surgery (2024)
Open Access | Times Cited: 1
Glycoconjugate Nanoparticle-Based Systems in Cancer Immunotherapy: Novel Designs and Recent Updates
Joseph J. Barchi
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 6
Chimeric antigen receptor-natural killer cells: a promising sword against insidious tumor cells
Tahereh Hojjatipour, Zahra Sharifzadeh, Amirhosein Maali, et al.
Human Cell (2023) Vol. 36, Iss. 6, pp. 1843-1864
Closed Access | Times Cited: 3
Role of NK Cells in Cancer and Immunotherapy
Paresh Vishwasrao, Susanta Hui, D. Lynne Smith, et al.
Onco (2021) Vol. 1, Iss. 2, pp. 158-175
Open Access | Times Cited: 6
Characterization of the biological and transcriptomic signatures of natural killer cells derived from cord blood and peripheral blood.
Leisheng Zhang, Sijun Yang, Hongjun Chen, et al.
PubMed (2023) Vol. 13, Iss. 8, pp. 3531-3546
Closed Access | Times Cited: 2
The Art of Bioimmunogenomics (BIGs) 5.0 in CAR-T Cell Therapy for Lymphoma Management
Dito Anurogo, Dewi Luthfiana, Nuralfin Anripa, et al.
Advanced Pharmaceutical Bulletin (2024) Vol. 14, Iss. 2, pp. 314-330
Open Access
Targeting Tumors
Safiya Mehraj, Shazia Ali
Advances in medical diagnosis, treatment, and care (AMDTC) book series (2024), pp. 93-122
Closed Access
Page 1 - Next Page

Scroll to top